Abstract
Sodium glucose Cotransporter-2 (SGLT2) inhibitors are a new class of drug approved for the treatment of type-2 diabetes; however they are also increasingly used off label in type-1 diabetic patients. SGLT2 Inhibitors work by increasing glucose excretion in urine. Euglycemic diabetic ketoacidosis (DKA) is potentially life threatening side effect as patients have normal glucose and minimal symptoms thus delaying diagnosis and treatment.Our case report highlights the risk ofusing SGLT2 inhibitors in type-1 diabetes and also supports the need for long term studies to define clear efficacy and complications of SGLT 2 inhibitors in both type-1 and type 2 diabetes mellitis
Hassan Tahir,Department of Internal Medicine, Temple University/Conemaugh Memorial Hospital, 1086 Franklin Street, , Adil Wani, , Vistasp Daruwalla,, Nour Daboul, , Jahnavi Sagi. (2015) EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT, JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD, Volume 27, Issue 4.
-
Views
536 -
Downloads
53
Article Details
Volume
Issue
Type
Language
